Naslov
Expert Discussion: ASCO 2022

Autori
Balic, Marija ; Wimmer, Kerstin ; Suppan, Christoph ; Silovski, Tajana ; Brunner, Christine

Izvornik
Breast Care (1661-3791) 17 (2022), 4; 430-436

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, stručni

Ključne riječi
Breast cancer, neoadjuvant and adjuvant treatment

Sažetak
PALOMA-2 OS data presented at ASCO lacked to demonstrate OS benefit in favor of palbociclib. Dr. Finn has implied that partly this was due to a significant proportion of patients who were lost to follow-up and the patient population.ADCs are changing the treatment landscape of metastatic breast cancer patients. So far, we have had approval of Her2-directed ADCs in Her2-positive breast cancer and Anti Trop II ADC sacituzumab govitecan in triple-negative breast cancer.In the early- stage breast cancer, pembrolizumab has been approved for neoadjuvant and adjuvant treatment of triple negative breast cancer. Update with RCB score analyses was presented at the ASCO annual meeting!

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA